Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Prepaid Assets (2016 - 2025)

CytomX Therapeutics' Prepaid Assets history spans 12 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 35.68% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, up 35.68%, while the annual FY2025 figure was $4.9 million, 35.68% up from the prior year.
  • Prepaid Assets reached $4.9 million in Q4 2025 per CTMX's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $7.5 million in Q4 2022 to a low of $3.1 million in Q2 2024.
  • Average Prepaid Assets over 5 years is $4.6 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Prepaid Assets: crashed 43.51% in 2021, then soared 74.24% in 2022.
  • A 5-year view of Prepaid Assets shows it stood at $4.3 million in 2021, then soared by 74.24% to $7.5 million in 2022, then plummeted by 33.1% to $5.0 million in 2023, then fell by 28.35% to $3.6 million in 2024, then soared by 35.68% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Prepaid Assets are $4.9 million (Q4 2025), $4.0 million (Q3 2025), and $4.7 million (Q2 2025).